Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Phenylpropanolamine→

Phenylpropanolamine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
14838-15-4
Molecular formula
C9H13NO
Molecular weight
151.21 g/mol
Drug class
Sympathomimetic aminepredominantly indirect adrenergic agonist and nasal decongestant
Mechanism of action
Primarily promotes norepinephrine release from sympathetic nerve terminals and also has direct agonist activity at adrenergic receptors. Alpha-adrenergic activity causes vasoconstriction of nasal mucosal vessels; beta-adrenergic effects may also occur.
Indications / reported uses
  • Historically used as an oral or topical nasal decongestant in some jurisdictions; current availability and permitted indications vary because of safety-related regulatory restrictions.
  • It has also been used as an appetite suppressant historically; this is not presented as a current routine therapeutic indication.

Sources: https://www.ncbi.nlm.nih.gov/mesh?Cmd=DetailsSearch&Term=%22Phenylpropanolamine%22%5BMeSH+Terms%5D · https://meshb.nlm.nih.gov/record/ui?dcmsLinks=true&ui=D010665 · https://pubchem.ncbi.nlm.nih.gov/compound/10297

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Phenylpropanolamine Environmental Risk Assessment (ERA) (the Phenylpropanolamine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.